Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos
Background: Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) at the present time. However, it rarely presents in the intranasal cavity as the primary site. There is scarcity of local data on this disease, and the outcomes to the standard treatment are still...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
West Asia Organization for Cancer Prevention
2022-05-01
|
| Series: | Asian Pacific Journal of Cancer Care |
| Subjects: | |
| Online Access: | http://www.waocp.com/journal/index.php/apjcc/article/view/756 |
| _version_ | 1797342254077050880 |
|---|---|
| author | Dean Marvin Potato Pizarro Mel Valerie Cruz-Ordinario Vivian Butalid Marie Belle Francia |
| author_facet | Dean Marvin Potato Pizarro Mel Valerie Cruz-Ordinario Vivian Butalid Marie Belle Francia |
| author_sort | Dean Marvin Potato Pizarro |
| collection | DOAJ |
| description | Background: Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) at the present time. However, it rarely presents in the intranasal cavity as the primary site. There is scarcity of local data on this disease, and the outcomes to the standard treatment are still unclear.
Objective: In this case series, we presented 2 patients with primary intranasal DLBCL that were treated with chemotherapy ± anti-CD20 antibody and radiotherapy.
Results: Both cases were in the early stage of disease. One patient was given systemic chemotherapy (CHOP) plus anti-CD20 antibody (Rituximab), and the other patient was only given chemotherapy (CHOP) due to financial constraints. The systemic treatment was followed by Involved-Field Radiotherapy (IFRT). Both patients demonstrated with an objective radiologic and clinical response to the treatment. The patients had no evidence of disease recurrence at 36 months.
Conclusion: The cases presented showed that primary intranasal DLBCL appears to have an objective and durable response to the treatment for DLBCL as prescribed by the guidelines. The findings in this study can be added to the pool of data to expand our comprehension of this disease process. |
| first_indexed | 2024-03-08T10:30:39Z |
| format | Article |
| id | doaj.art-99a9631134a04cb1b525f395787ec796 |
| institution | Directory Open Access Journal |
| issn | 2588-3682 |
| language | English |
| last_indexed | 2024-03-08T10:30:39Z |
| publishDate | 2022-05-01 |
| publisher | West Asia Organization for Cancer Prevention |
| record_format | Article |
| series | Asian Pacific Journal of Cancer Care |
| spelling | doaj.art-99a9631134a04cb1b525f395787ec7962024-01-27T05:36:00ZengWest Asia Organization for Cancer PreventionAsian Pacific Journal of Cancer Care2588-36822022-05-017240540810.31557/apjcc.2022.7.2.405-408756Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among FilipinosDean Marvin Potato Pizarro0Mel Valerie Cruz-Ordinario1Vivian Butalid2Marie Belle Francia3St. Luke's Medical CenterSt. Luke’s Medical Center, PhilippinesSt. Luke’s Medical Center, PhilippinesSt. Luke’s Medical Center, PhilippinesBackground: Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) at the present time. However, it rarely presents in the intranasal cavity as the primary site. There is scarcity of local data on this disease, and the outcomes to the standard treatment are still unclear. Objective: In this case series, we presented 2 patients with primary intranasal DLBCL that were treated with chemotherapy ± anti-CD20 antibody and radiotherapy. Results: Both cases were in the early stage of disease. One patient was given systemic chemotherapy (CHOP) plus anti-CD20 antibody (Rituximab), and the other patient was only given chemotherapy (CHOP) due to financial constraints. The systemic treatment was followed by Involved-Field Radiotherapy (IFRT). Both patients demonstrated with an objective radiologic and clinical response to the treatment. The patients had no evidence of disease recurrence at 36 months. Conclusion: The cases presented showed that primary intranasal DLBCL appears to have an objective and durable response to the treatment for DLBCL as prescribed by the guidelines. The findings in this study can be added to the pool of data to expand our comprehension of this disease process.http://www.waocp.com/journal/index.php/apjcc/article/view/756nasaldiffuse large b-cell lymphomanon-hodgkin lymphomarare diseasestreatment outcome |
| spellingShingle | Dean Marvin Potato Pizarro Mel Valerie Cruz-Ordinario Vivian Butalid Marie Belle Francia Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos Asian Pacific Journal of Cancer Care nasal diffuse large b-cell lymphoma non-hodgkin lymphoma rare diseases treatment outcome |
| title | Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos |
| title_full | Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos |
| title_fullStr | Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos |
| title_full_unstemmed | Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos |
| title_short | Case Series of Rare Primary Intranasal Diffuse Large B-cell Lymphoma among Filipinos |
| title_sort | case series of rare primary intranasal diffuse large b cell lymphoma among filipinos |
| topic | nasal diffuse large b-cell lymphoma non-hodgkin lymphoma rare diseases treatment outcome |
| url | http://www.waocp.com/journal/index.php/apjcc/article/view/756 |
| work_keys_str_mv | AT deanmarvinpotatopizarro caseseriesofrareprimaryintranasaldiffuselargebcelllymphomaamongfilipinos AT melvaleriecruzordinario caseseriesofrareprimaryintranasaldiffuselargebcelllymphomaamongfilipinos AT vivianbutalid caseseriesofrareprimaryintranasaldiffuselargebcelllymphomaamongfilipinos AT mariebellefrancia caseseriesofrareprimaryintranasaldiffuselargebcelllymphomaamongfilipinos |